TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Last week was another busy week for the White House, with several notable Executive Orders and more agency leadership changes ...

Cowen challenged students to rethink the intersection of society and artificial intelligence at a Yale Political Union debate ...

The widely followed cryptocurrency analyst Benjamin Cowen is warning that Ethereum (ETH) could slide further against Bitcoin ...

President Donald Trump appointed William Cowan as acting general counsel of the National Labor Relations Board Monday evening ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

The analysts say a bundle is a better model for traditional TV giants like WBD, Disney, and Paramount. Netflix is another ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

TD Cowen analyst Jared Levine raised the firm’s price target on Paylocity (PCTY) to $242 from $228 and keeps a Buy rating on the shares. The ...

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...